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1. Introduction
Neuroblastoma (NB) patients fall into two clinically distinct subgroups; a low-risk subgroup
and a high-risk subgroup. These subgroups are correlated with the age of onset [1], the extent
of the disease (International Neuroblastoma Staging System) [2], pathological findings
(International Neuroblastoma Pathological Criteria) [3], and genomic changes in NB tumors
as represented by MYCN gene amplification (MNA) [4, 5]. Above all, the patterns of genetic
changes can predict the subgroups of NB [6]. The low-risk, favorable NBs have mitotic
disorders, and are characterized by near triploid karyotypes with whole chromosomal gains.
On the other hand, the high-risk, unfavorable NBs exhibit genetic instability, and are charac‐
terized by chromosomal structural changes, including deletion of 1p or 11q, unbalanced gain
of 17q, and/or MNA. MNA is the most powerful prognostic factor identified so far, and is
useful regardless of the tumor stage. In the recent studies, the 5-year event free survival of
patients who had NB tumors with MNA was 53% for localized NB [7] and 29% for all NBs [8],
even with intensive, multimodal treatment. On the other hand, NB without MYCN amplifi‐
cation (non-MNA) falls into another two clinically distinct subgroups: a low-risk subgroup
with overall survival rates of more than 95% without any intensive therapy, and a high-risk
subgroup with overall survival rates of less than 40% despite the use of dose-intensive,
multimodal therapy. In the high-risk non-MNA group, the development of NB depends on
factors other than MNA, such as the expression profiles of other genes [9], aberrant hyperme‐
thylation of tumor suppressor genes [10], and chromosomal loss of heterozygosity (LOH) [11].
To determine the stratification of NB patients more precisely with regard to the treatment
approach, a screen for these genetic aberrations should be performed before the initial
treatment. Indeed, in the INRG staging system, routine assessments of MNA and 11q loss were
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required for the therapeutic stratification of NB [8]. Currently, genetic alterations in NB tumors
are clinically evaluated by interphase dual-color fluorescence in situ hybridization (I-FISH),
array comprehensive genomic hybridization (aCGH), PCR and multiple ligation probe
amplification (MLPA) [12]. However, the evaluation of tumor-related genetic aberrations
requires a fresh tumor sample, which is often difficult to obtain due to the frequent occurrence
of life-threatening conditions in NB patients.
Recent improvements in molecular techniques such as PCR have made it possible to detect
small amounts of cell-free DNA in the serum and plasma of patients with various diseases,
including cancers. In particular, tumor-derived cell-free DNA has attracted attention as a novel
genetic marker for cancer. Other improvements in molecular techniques have enabled the
evaluation of tumor-related genetic aberrations using small amounts of cell-free DNA in the
serum. NB has been detected with several tumor-related genetic alterations, such as RAS
mutations [13], or TP53 mutations [14], microsatellite instability [15], gene amplification [16,
17], aberrant promoter hypermethylation [18, 19], and allelic gain and loss of oncogenes [15,
20, 21].
We have been attempting to establish a preoperative risk stratification system for NB based
on a serum-based assay system for MYCN gene amplification, aberrant promoter hyperme‐
thylation, and chromosomal loss of 11q. These less invasive techniques are clinically useful for
the preoperative risk stratification of NB patients, because genomic changes in the tumor
correlate with the tumor behavior, survival outcome, and response to therapy of NB patients.
In this paper, we provide an update on the novel serum-based system for evaluating genetic
aberrations for the risk stratification of patients with NB, including our recent studies.
2. Methods and results
Serum samples were collected from the patients with NB before initial treatment. Cellular
components were immediately removed from the collected sera immediately by centrifugation
or filtration. DNA fragments were purified from 200μl of serum according to manufacturer’s
protocol and were used for further genetic analysis as mentioned below.
2.1. Detection of amplified MYCN gene in the sera of NB patients
The MYCN oncogene can be detected in the serum of patients with MNA-NB. We previously
established a system for quantitatively evaluating system of MYCN gene copy number using
serum DNA of NB patients [17]. We simultaneously quantified the dosages of the MYCN gene
located on 2p24 as a target, and the NAGK gene located on 2p12 as a reference by real-time
PCR using DNA samples obtained from paired serum and tumor samples before the initial
treatment. Also, we evaluated the MYCN gene copy number to obtain the MYCN/NAGK ratio.
The MYCK/NAGK ratios of serum DNA and tumor DNA were strongly correlated, and the
serum MYCN/NAGK ratio in the MNA group was significantly higher than the ratio in the
non-MNA group. Notably, the sensitivity and specificity of the serum MYCN/NAGK ratio as
a diagnostic test were both 100% when the serum MYCN/NAGK ratio cutoff was set at 10.0
Neuroblastoma14
(Figure 1). We also reported that the serum-based MYCN status was an indicator of therapeutic
efficacy. Among six MNA patients whose clinical courses were followed, the serum ratios
decreased to within the normal range in the patients in remission (n=3), whereas the ratios
increased to high levels in the patients who relapsed (n=2) or failed to achieve remission (n=1).
These data strongly suggested that the serum-based quantitative MYCN status was a useful
tool for preoperatively determining the stratification for therapy and for the evaluation of
therapeutic efficacy during the course of treatment, when tumor cells were not available for a
molecular analysis. Considering that it is often impossible to obtain tumor samples from
patients with advanced NB for biological studies due to their life-threatening conditions, these
data may have important clinical implications.
Figure 1. A scatter plot of serum MYCN/NAGK ratio according to tumor MYCN status. The serum MYCN/NAGK ratio
was significantly (p<0.001) higher in the MNA group (median, 199.32; range, 17.1 to 901.6; 99% CI, 107.0 to 528.7)
than in the non-MNA group (median, 0.87; range, 0.25 to 4.6; 99% CI, 0.82 to 1.26; Mann-Whitney U test). Adopted
from Ref. [17]
Combaret et al., who first reported the existence of the MYCN gene in the sera of NB patients
confirmed our data using a European cohort and the same method that we used. Also, they
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indicated that the sensitivity of serum-based MYCN status depends on the stage of NB and is
lower for patients with locoregional NB [22]. Indeed, they analyzed 10 serum samples obtained
at diagnosis from MNA-NB patients with INSS stages 1 and 2, and 16 serum samples from
MNA-NB patients with INSS stage 3 disease, and revealed that only one of 10 patients with
stage 1 and 2 disease, and 12 of the 16 INSS patients with stage 3 disease showed high levels
of circulating MYCN DNA sequences (10% and 75% sensitivity, respectively). In contrast,
significant levels of circulating MYCN DNA sequences were detected in the patients with stage
4 disease and MNA (85% sensitivity).
We also confirmed the sensitivity and specificity of serum MNA analysis using 148 samples
obtained from NB patients with various INSS stages in two Japanese cohorts other than ours
and a cohort from the Children Oncology Group. A sub-group analysis according to INSS
stages revealed that the sensitivities and specificities were not statistically different (67% and
95%, respectively, in stages 1 and 2, 92% and 86% in stage 3, and 87% and 97% in stage 4),
although the number of each group was not statistically sufficient (p=0.48 for sensitivity, p=0.68
for specificity, chi-squared test) (our unpublished data). Accordingly, the serum MYCN/NAGK
ratio would be a specific tool for the prediction of tumor MYCN amplification in patients with
NB regardless of tumor stage, even though the sensitivity of serum MNA analysis showed a
tendency to be low among the patients with INSS stages 1 and 2. Indeed, for most therapeutic
regimens, primary radical resection is recommended for localized non-MNA NB. Moreover,
up-front surgical resection is not indicated for advanced localized NB, including tumors with
MNA. Therefore, knowing the preoperative serum-based MYCN status should result in better
decision-making, especially for localized NB. As mentioned above, circulating tumor-derived
cell-free DNA could be detected in the serum of cancer patients regardless of the tumor stage.
Therefore, it was of interest to determine whether the serum-based MYCN status was also
useful to determine the risk classification for localized NB. Being able to determine the MYCN
status of NB patients from a blood sample would be very useful for cases who cannot provide
tumor samples for a molecular analysis.
2.2. Detection of methylated DNA fragments in the sera of NB patients
It is important to have additional biomarkers with prognostic value for the management of
non-MNA cases of NB because some cases without MNA also have a poor prognosis. Recent
studies have revealed that epigenetic alterations, such as silencing of tumor suppressor genes
by aberrant hypermethylation of the promoter, often play important roles in the pathogenesis
and progression of NB. A positive correlation has been found between the hypermethylation
of the promoters of these genes and a poor prognosis, thus suggesting that hypermethylation
influences the phenotype of neuroblastoma.
We previously revealed that the aberrant hypermethylation in the promoter region of the
DCR2 gene in serum is a potent prognostic factor especially in non-MNA NB [18]. DCR2 (decoy
receptor 2) is a tumor necrosis factor alpha receptor superfamily gene, and is negatively
associated with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced
apoptosis, because it lacks an intracellular death domain [23]. In NB tumors, the methylation
profile of DCR2 has been found to be drastically different and independent of the MYCN status
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[10, 24, 25]. Moreover, DCR2 methylation was found to be associated with rapidly progressing
tumors and a reduced overall survival [10]. Using the methylation-specific real-time PCR
analysis we established [18], the aberrant hypermethylation in the promoter region of DCR2
gene could also be detected in the serum DNA, and strongly correlated with the expression in
the tumor. The 5-year event-free survival and overall survival of NB patients with methylated
DCR2, as detected by a serum-based assay, were significantly poorer than those of NB patients
with unmethylated DCR2 [18] (Figure 2). These observations indicated that the serum-based
DCR2 methylation status could help predict the prognosis of NB patients, especially those
without MNA. Additionally, the serum-based DCR2 methylation status can distinguish
patients with a poor outcome within the non-MNA group, and may allow for a new type of
risk stratification for patients with non-MNA NB in future trials.
Figure 2. Event-free and overall survival for patients with neuroblastoma according to the serum-based DCR2 methyl‐
ation status. A: Event-free survival in all patients with neuroblastoma: methylated (n = 24) and unmethylated (n = 62);
P < 0.001. B: Event-free survival in patients with non-MNA neuroblastoma: methylated (n = 15) and unmethylated (n =
53); P < 0.001. C: Overall survival in all patients with neuroblastoma: methylated (n = 24) and unmethylated (n = 62); P
= 0.008. D: Overall survival in patients with non-MNA neuroblastoma: methylated (n = 15) and unmethylated (n = 53);
P < 0.001. Adopted from Ref. [18]
RASSF1A is hypermethylated in 93-94% of NB primary tumors and in 100% of relapsed tumors
[19, 26]. RASSF1A hypermethylation in tumors appears to be a relatively early event in NB
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tumorigenesis, as it is usually detectable in early stage tumors. On the other hand, RASSF1A
methylation was detected in the serum from only 25% of NB patients, and methylated
RASSF1A was more frequently detectable in the serum of advanced NB patients than in those
with early stage NB, although the RASSF1A methylation status in NB tumors was not
significantly different between patients with advanced and early stage NB. These discrepan‐
cies in the sensitivities between serum-based and tumor-based methylation assays could be
explained by the smaller quantity of DNA released from a small tumor burden. Nevertheless,
this serum-based RASSF1A methylation assay should help to determine the appropriate risk
classification.
2.3. Detection of chromosomal loss and gain in the serum DNA of NB patients
Chromosomal gain and/or loss are frequently observed in NB as mentioned above. Among
the various unbalanced chromosomal aberrations, 17q gain is the most frequent chromosomal
aberration, and correlates with a poor outcome [27]. The loss of 11q is also a strong prognostic
factor that can be used in addition to MNA [11], and routine assessment of the 11q status, as
well as MNA, is required for therapeutic stratification of NB in the INRG staging system [8].
Some groups, including ours, have developed serum-based assays to detect chromosomal gain
and/or loss in NB using various techniques. Combaret et al. reported a serum-based detection
system for 17q gain [20]. They simultaneously quantified the gene dose of MPO (17q.23.1) and
survivin (17q25) as targets, and p53 as a reference, by quantitative real-time PCR using 142
serum samples. They revealed that the serum-based determination of 17q gain had good
specificity (94.4%) and sensitivity (58.8%) in patients who were less than 18 months old
(p<0.001), while this approach showed moderate specificity (71.4%) and sensitivity (51.2%) in
patients over 18 months of age. In a subset analysis according to the stage of NB, the sensitivity
of serum-based 17q gain determination tended to increase with the stage of the disease. On
the other hand, for metastatic NB, the sensitivity of the test never exceeded 60%, which is lower
than the results achieved by the analysis of the serum-based MYCN status.
We developed an assay for detecting chromosomal aberration of 11q, using a different method
that doesn’t use quantitative real-time PCR. Previous studies have revealed the presence of a
smallest region of overlap (SRO), which is a common region of deletion in all NB cases with
11q loss. By targeting some polymorphic markers in the SRO of 11q (most of which are located
in 11q23), allelic loss could be detected using serum DNA as well as tumor DNA of NB patients
[21] (Figure 3). Using this technique, the sensitivity and specificity of the results between the
serum- and tumor-based 11q loss analyses were both 100%, although a further study is needed
to confirm of these findings because of the limited number of cases that were analyzed.
3. Discussion
In a large-scale randomized trial of children with high-risk NBs [28], the MYCN status was
unknown in 27% of the children. In a clinical setting, some life-threatening cases with a huge
mass or hepatomegaly (hepatic metastasis in stage 4s) received chemotherapy and/or radio‐
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therapy based on elevated tumor markers and positive MIBG scintigraphy, prior to tumor
biopsy without evaluation of the MYCN status. The serum-based assays described above will
be most useful when a primary tumor biopsy is not possible and when genetic information
will influence the risk grouping and treatment allocation of the NB patients.
In Japan, infantile NB cases were formerly subclinically detected by mass-screening. Most of
these cases showed a good prognosis and were recommended to undergo a reduced regimen,
including the “wait-and-see” approach. However, we and others demonstrated that MNA was
strongly correlated with a poor prognosis even in infantile, localized NB [7, 29]. The serum-
based MNA status has considerable prognostic value for infantile NB cases. Indeed, the serum-
based MNA status of NB patients has considerable prognostic value, especially in cases less
than 18 months of age (our unpublished data).
On the other hand, most of the infantile, localized NB patients did not have MNA. In the
Cooperative German Neuroblastoma NB95 and NB97 trials, some localized patients without
MNA did not receive chemotherapy after biopsy and showed spontaneous regression [30].
Considering the clinical behavior of non-MNA NB, an early and non-invasive system for
detecting genetic alterations besides MNA is needed to help select the appropriate therapy. In
other words, combined preoperative assessments of MNA and 11q loss using serum DNA will
make it possible to safely perform risk-adapted therapy according to the INRG staging system
Figure 3. Representative case of 11q loss. The results of 11q microsatellite analysis were shown. This case was a neuro‐
blastoma categorized into low-risk subgroup (INSS stage2, MYCN non-amplified NB, Shimada: Favorable Histology).
Complete resection after initial diagnosis was performed without any additional chemotherapy. Relapse at bone and
bone marrow 1 year after resection was observed, and he died of disease 3year after relapse. Microsatellite analysis
were performed using his serum, tumor and leucocyte DNA, and STS marker D11S4127 located on 11q 23.3. Non-
tumor DNA purified from leukocytes has two fluorescent peaks (shown in blue), whereas in tumor and serum DNA,
one of the peaks is reduced, suggesting the existence of 11q loss. Adopted from Ref. [21].
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[8]. Particularly, preoperative serum-based MNA and 11q loss detection can be useful for cases
that are in INRG stages L2 and MS, which have a wide range of clinical outcomes and potential
therapeutic strategies depending on the existence of MNA and 11q loss. Further, we may be
able to select infants with NB who truly need to receive treatment including surgical treatment,
intensive chemotherapy, and even radiotherapy from infants with NB who do not need to
require any treatment by using our technique.
In conclusion, serum-based, less invasive molecular analysis can provide much better clinical
information to determine the optimal therapeutic strategy for NB patients. Prospective
validation in a large cohort will be needed to confirm the utility of these tools for assessing
biological risk. Serum-based, surgery-free, rapid, sensitive, and specific genetic assessments
have great potential to provide a personalized, risk-adapted therapy for patients with NB.
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